Variable | Total population (n = 5298) | Non-MACCEs (n = 4199) | MACCEs (n = 1099) | P value |
---|---|---|---|---|
FAR | 0.081 ± 0.022 | 0.080 ± 0.022 | 0.082 ± 0.024 | 0.010 |
Four subgroups, n (%) |  |  |  |  < 0.001 |
 FAR-H/DM | 1116 (21.1) | 829 (19.7) | 287 (26.1) |  |
 FAR-L/DM | 1189 (22.4) | 941 (22.4) | 248 (22.6) |  |
 FAR-H/Non-DM | 1265 (23.9) | 1018 (24.2) | 247 (22.5) |  |
 FAR-L/Non-DM | 1728 (32.6) | 1411 (33.6) | 317 (28.8) |  |
Baseline characteristics | ||||
 Age, years | 58.36 ± 10.36 | 58.12 ± 10.26 | 59.30 ± 10.68 | 0.001 |
 Male, n (%) | 4,119 (77.7) | 3,246 (77.3) | 873 (79.4) | 0.130 |
 BMI, kg/m2 | 25.89 ± 3.15 | 25.92 ± 3.15 | 25.81 ± 3.15 | 0.338 |
 DM, n (%) | 2305 (43.5) | 1770 (42.2) | 535 (48.7) |  < 0.001 |
 Hypertension, n (%) | 3386 (63.9) | 2629 (62.6) | 757 (68.9) |  < 0.001 |
 Dyslipidemia, n (%) | 3657 (69.0) | 2889 (68.8) | 768 (69.9) | 0.491 |
 Smoking history, n (%) | 3107 (58.6) | 2435 (58.0) | 672 (61.1) | 0.059 |
 Family history of CAD, n (%) | 1222 (23.1) | 948 (22.6) | 274 (24.9) | 0.101 |
 Previous MI, n (%) | 1036 (19.6) | 791 (18.8) | 245 (22.3) | 0.010 |
 Previous PCI, n (%) | 1229 (23.2) | 914 (21.8) | 315 (28.7) |  < 0.001 |
 Previous stroke, n (%) | 556 (10.5) | 419 (10.0) | 137 (12.5) | 0.017 |
 Previous PAD, n (%) | 150 (2.8) | 120 (2.9) | 30 (2.7) | 0.820 |
 Clinical presentation, n (%) |  |  |  | 0.435 |
  CCS | 2258 (42.6) | 1801 (42.9) | 457 (41.6) |  |
  ACS | 3040 (57.4) | 2398 (67.1) | 642 (58.4) |  |
Laboratory tests | ||||
 FIB, g/L | 3.38 ± 0.83 | 3.37 ± 0.82 | 3.43 ± 0.85 | 0.047 |
 Albumin, g/L | 42.40 ± 3.83 | 42.45 ± 3.84 | 42.22 ± 3.79 | 0.079 |
 FBG, mmol/L | 6.02 ± 1.97 | 5.99 ± 1.93 | 6.16 ± 2.11 | 0.012 |
 HbA1c, % | 6.59 ± 1.21 | 6.56 ± 1.21 | 6.72 ± 1.21 |  < 0.001 |
 TG, mmol/L | 1.80 ± 1.09 | 1.80 ± 1.10 | 1.80 ± 1.02 | 0.895 |
 TC, mmol/L | 4.17 ± 1.09 | 4.17 ± 1.08 | 4.16 ± 1.90 | 0.883 |
 HDL-C, mmol/L | 1.02 ± 0.27 | 1.02 ± 0.28 | 1.01 ± 0.27 | 0.158 |
 LDL-C, mmol/L | 2.48 ± 0.91 | 2.48 ± 0.91 | 2.48 ± 0.91 | 0.971 |
 hs-CRP, mg/L | 3.07 ± 3.68 | 2.99 ± 3.63 | 3.36 ± 3.87 | 0.006 |
 Creatinine, μmol/L | 75.33 ± 15.95 | 74.98 ± 15.50 | 76.68 ± 17.52 | 0.004 |
 eGFR, mL/min/1.73 m2 | 91.63 ± 15.10 | 92.01 ± 14.72 | 90.18 ± 16.41 | 0.001 |
 LVEF, % | 63.23 ± 7.04 | 63.38 ± 6.92 | 62.67 ± 7.47 | 0.005 |
Medications at admission | ||||
 Aspirin, n (%) | 5245 (99.0) | 4157 (99.0) | 1088 (99.0) | 0.998 |
 Clopidogrel, n (%) | 5286 (99.8) | 4190 (99.8) | 1096 (99.7) | 0.716 |
 β-blocker, n (%) | 4829 (91.1) | 3822 (91.0) | 1007 (91.6) | 0.528 |
 CCB, n (%) | 2485 (46.9) | 1941 (46.2) | 544 (49.5) | 0.053 |
 Statins, n (%) | 5112 (96.5) | 4054 (96.5) | 1058 (96.3) | 0.656 |
 Nitrate, n (%) | 5162 (97.4) | 4082 (97.2) | 1080 (98.3) | 0.048 |
 Insulin, n (%) | 613 (11.6) | 456 (10.9) | 157 (14.3) | 0.002 |
Coronary procedural information | ||||
 LM/three-vessel disease, n (%) | 2382 (45.0) | 1806 (43.0) | 576 (52.4) |  < 0.001 |
 Chronic total occlusion, n (%) | 377 (7.1) | 291 (6.9) | 86 (7.8) | 0.304 |
 Target vessel territory, n (%) |  |  |  |  < 0.001 |
  LAD | 2512 (47.4) | 2073 (49.4) | 439 (39.9) |  |
  LCX | 955 (18.0) | 739 (17.6) | 216 (19.7) |  |
  RCA | 1757 (33.2) | 1334 (31.8) | 423 (38.5) |  |
 Number of stents | 1.77 ± 0.89 | 1.76 ± 0.90 | 1.79 ± 0.86 | 0.303 |
 SYNTAX score | 11.79 ± 9.06 | 11.61 ± 7.90 | 12.47 ± 8.62 | 0.003 |
 Complete revascularization, n (%) | 5268 (99.4) | 4179 (99.5) | 1089 (99.1) | 0.088 |
 DES implantation, n (%) | 5226 (98.6) | 4148 (98.8) | 1078 (98.1) | 0.076 |